echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Bristol-Myers Squibb relatlimab for the treatment of melanoma

    Bristol-Myers Squibb relatlimab for the treatment of melanoma

    • Last Update: 2022-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    In 2021, the U.



    The U.
    FDA has approved BMS Class 2 checkpoint inhibitors
    By mid-March, the third category
    may be approved.
    Currently, the agency is reviewing BMS's in-research immunotherapy, relatlimab
    The drug targets early immune checkpoint inhibitors from BMS and other companies (e.
    , Merck, Roche, Renewable), which work by blocking CTLA-4, PD-1, or PD-L1 proteins, while relatlimab acts on a protein
    called LAG-3.
    However, the mechanism behind these drugs is similar: by blocking these proteins, anti-cancer immune cells are helped target and attack tumor cells

    Approval of relatlimab is important both in the field of immunotherapy and BMS
    In the field of immunotherapy, years have previously been spent looking for additional ways to unlock the immune system's ability to
    fight cancer.
    For BMS, the company has lost its early market advantage
    over Merck.

    The FDA will review Relatlimab on March 19
    Clinical trials have shown that in patients with melanoma that has spread or cannot be surgically removed, relatlimab + Opdivo dual immunotherapy significantly reduces the risk of
    cancer progression compared with Opdivo monotherapy.
    This result is the first time that targeting LAG-3 has been clearly demonstrated to be beneficial, and the first time that a protocol can provide improved results
    compared to Opdivo.

    Gilead lenacapavir for HIV

    Gilead lenacapavir for HIV

    Gilead has maintained an industry-leading business
    in HIV treatment for many years.
    In the first nine months of 2021 alone, the company's HIV business generated about $11.
    8 billion in sales
    However, due to competition from strong rivals such as Merck, Johnson & Johnson and GlaxoSmithKline, Gilead is still under pressure
    to innovate.
    In this regard, a drug called lenacapavir becomes very important
    for Gilead's future.

    lenacapavir is a potentially pioneering long-acting HIV-1 capsid inhibitor that inhibits HIV-1 replication by interfering with several important steps in the viral life cycle, including capsid-mediated uptake of HIV-1 previral DNA, assembly and release of the virus, and formation
    of the capsid core.

    Gilead has achieved positive clinical trial results: lenacapavir has shown significant efficacy in patients with MDR-resistant HIV who have tried multiple other therapies and are no longer effective
    Of the patients treated to date, approximately 80% of patients achieved an undetectable viral load after 6 months of treatment with lenacapavir and an optimized background regimen

    Based on these results, Gilead filed a listing application for
    lenacapavir with the U.
    FDA last summer.
    The FDA expects to make a review decision
    on February 28.
    If approved, lenacapavir would be the first ever capsid inhibitor to be marketed and the only HIV treatment option
    to be administered every 6 months.

    Akabegia vadadustat for renal anemia

    Akabegia vadadustat for renal anemia

    Not long ago, a group of oral drugs known as HIF-PH inhibitors were considered the next important drug
    for treating anemia in patients with chronic kidney disease.
    But their potential as a convenient and safe alternative to injectable drugs such as Aranesp has dimmed

    In 2020, vadadustat, a drug from Akebia Therapeutics, appears to be worse
    than Aranesp in terms of cardiac safety in a Phase 3 clinical trial.
    Subsequently, the FDA and its advisory board rejected FibroGen's drug of the same type, roxadustat, which has been approved
    in several other countries.
    The FDA and its advisory board have expressed concern about
    the cardiovascular risks of roxadustat.
    Since then, Faber has restructured, while Akebia's stock trading is at an all-time

    However, HIF-PH inhibitors still have a future in the
    United States.
    Last November, GlaxoSmithKline announced detailed positive results from a Phase 3 clinical trial of daprodustat, which was also approved
    outside the United States.
    Akebia, for its part, filed a listing application despite setbacks, claiming that its full findings were sufficient to ensure regulatory approval

    That belief will be tested
    this quarter.
    While analysts have been skeptical that the drug can be approved in the broadest population of people with chronic kidney disease, some believe the FDA will approve the drug for dialysis patients, who still represent a considerable market
    The FDA will make a decision
    by March 29.

    AstraZeneca/Merck Lynparza for the treatment of early breast cancer

    AstraZeneca/Merck Lynparza for the treatment of early breast cancer

    Lynparza, an anti-cancer drug known as a PARP inhibitor, is an industry leader in its class, has received regulatory approval in multiple tumor types, and in the process has become a multibillion-dollar drug
    However, if the FDA approves it for the early treatment of a particularly aggressive hereditary breast cancer, the drug's biggest impact to date could soon come

    In a Phase 3 trial last year, Lynparza adjuvant therapy reduced the risk
    of cancer recurrence in patients with BRCA1 or BRCA2 mutation HER2-negative early breast cancer who had completed topical therapy and standard neoadjuvant or adjuvant chemotherapy.
    BRCA1 and BRA2 are two gene mutations that account for about 5%
    of all breast cancer cases.

    Experts who were not affiliated with the study and were interviewed by BioPharma Dive said the findings have the potential to change clinical practice
    But key questions remain, most notably how long Lynparza will be able to extend its lifespan and whether the advent of the drug will encourage BRCA testing
    If approved, Lynparza will also be the latest high-priced anticancer drug to enter the earlier treatment of cancer, which is widely seen as a very lucrative market opportunity for

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.